| Market Cap | 156.51M | P/E | - | EPS this Y | -31.40% | Ern Qtrly Grth | - |
| Income | -44.75M | Forward P/E | -2.07 | EPS next Y | -39.30% | 50D Avg Chg | 27.00% |
| Sales | 21.18M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 24.00% |
| Dividend | N/A | Price/Book | 2.75 | EPS next 5Y | - | 52W High Chg | - |
| Recommedations | 3.00 | Quick Ratio | 2.98 | Shares Outstanding | 21.98M | 52W Low Chg | 244.00% |
| Insider Own | 3.71% | ROA | -21.63% | Shares Float | 21.58M | Beta | -0.35 |
| Inst Own | 44.96% | ROE | -60.87% | Shares Shorted/Prior | 1.23M/0.91M | Price | 7.12 |
| Gross Margin | 100.00% | Profit Margin | -211.32% | Avg. Volume | 724,583 | Target Price | 7.00 |
| Oper. Margin | -162.23% | Earnings Date | Aug 9 | Volume | Change | 0.00% |
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited.
| HC Wainwright & Co. | Neutral | Jul 15, 22 |
| SVB Leerink | Market Perform | Jun 24, 22 |
| SVB Leerink | Outperform | May 11, 22 |
| HC Wainwright & Co. | Buy | Mar 17, 22 |
| SVB Leerink | Outperform | Aug 17, 21 |
| SVB Leerink | Outperform | Jul 8, 21 |
| B. Riley Securities | Buy | Jun 9, 21 |
| HC Wainwright & Co. | Buy | May 18, 21 |
| Oppenheimer | Outperform | Apr 16, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Forster Eliot | President and CEO President and CEO | Jul 29 | Option | 0.11 | 260,977 | 28,707 | 421,537 | 08/02/22 |
| Brewis Neil | Chief Scientific Off.. Chief Scientific Officer | Jul 29 | Option | 0.11 | 76,619 | 8,428 | 114,463 | 08/02/22 |
| Kayitalire Louis | Chief Medical Office.. Chief Medical Officer | Nov 02 | Sell | 6.83 | 64 | 437 | 54,255 | 11/04/21 |